INFINITY PHARMACEUTICALS INC (INFI) Stock Analyst Ratings
USA - NASDAQ:INFI - US45665G3039 - Common Stock
0.0447 USD
-0.04 (-46.98%)
0.04 USD
0 (-10.51%)
ChartMill assigns a Buy % Consensus number of 43% to INFI. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 0.31. This target is 584.56% above the current price.
INFI was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about INFI.
In the previous month the buy percentage consensus was at a similar level.
INFI was analyzed by 6 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-02-24 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2022-11-16 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2022-05-23 | Piper Sandler | Maintains | Overweight |
| 2021-10-18 | HC Wainwright & Co. | Initiate | Buy |
| 2021-08-02 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2021-07-28 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2021-03-18 | Truist Securities | Initiate | Buy |
| 2021-03-17 | Wells Fargo | Maintains | Equal-Weight |
| 2021-02-18 | Piper Sandler | Initiate | Overweight |
INFINITY PHARMACEUTICALS INC / INFI FAQ
Can you provide the average price target for INFINITY PHARMACEUTICALS INC stock?
6 analysts have analysed INFI and the average price target is 0.31 USD. This implies a price increase of 584.56% is expected in the next year compared to the current price of 0.0447.
What is the consensus rating for INFI stock?
The consensus rating for INFINITY PHARMACEUTICALS INC (INFI) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
How many analysts cover INFINITY PHARMACEUTICALS INC (INFI) stock?
The number of analysts covering INFINITY PHARMACEUTICALS INC (INFI) is 6.